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ABSTRACT 
Hepatitis B virus (HBV) infection represents a significant public health burden worldwide. 
Although current therapeutics manage to control the disease progression, lifelong treatment and 
surveillance are required because drug resistance develops during treatment and reactivations 
frequently occur following medication cessation. Thus, the occurrence of hepatocellular 
carcinoma (HCC) is decreased but not eliminated. One major reason for the treatment failure is 
the inability to eradicate or inactivate the viral covalently closed circular DNA (cccDNA) which 
is a stable episomal form of viral genome decorated with host histones and non-histone proteins. 
Accumulating evidence suggests that epigenetic modifications of cccDNA contribute to viral 
replication and the outcome of chronic HBV infection. Here, we summarize the progress on 
HBV epigenetics research and the therapeutic implications for chronic HBV infection by 
learning from the epigenetic therapies for cancer and other viral diseases, which may open a new 
venue to cure the chronic hepatitis B.  
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INTRODUCTION 
Hepatitis B virus (HBV) infection remains a significant public health problem worldwide. The 
outcome of HBV infection is determined by multiple host and virus factors and the infection can 
be acute, chronic or occult(1). Chronic hepatitis B (CHB) affects more than 240 million 
individuals worldwide which are at risk of developing fibrosis, cirrhosis, liver failure and 
hepatocellular carcinoma (HCC)(2). The therapeutic goal of CHB is to decrease the risk of liver 
diseases progression and prevent its detrimental clinical sequelae, which can be partly achieved 
by sustained suppression of the virus replication, or ideally by eradicating the virus infection(3). 
Currently, US FDA-approved drugs for CHB treatment include two formulations of interferon 
alpha (standard and pegylated, IFN-α and pegIFN-α, respectively) that modulate the host 
antiviral immune response, and five nucleos(t)ide analogues (NUCs) including lamivudine, 
adefovir, entecavir, telbivudine and tenofovir that inhibit the HBV reverse transcription(4). 
Current therapies could lead to suppression of viral replication, resulting in normalization of 
serum alanine transaminase and improvement of liver histology(5). However, even prolonged 
treatments rarely cure the chronic infection, drug resistance occurs during treatment of NUCs, 
and virological relapse is common after treatment cessation(4). Strong evidence suggests that the 
lack of curativeness of current antiviral therapies is due to the inability to eliminate the episomal 
HBV covalently closed circular DNA (cccDNA), which serves as the persistent form of the viral 
genome and the transcription template for virus reproduction(6,7).  
 
The term ‘epigenetics’ refers specifically to the heritable alterations in gene expression that 
occurs to chromosome without changes in DNA sequence(8). Epigenetic regulation mechanisms 
include but may not be limited to DNA methylation, histone modifications, chromatin 
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remodeling and noncoding RNA (ncRNA) interference. HBV cccDNA exists in the nucleus as 
multiple copies of nucleosome-decorated minichromosomes(9,10), which implies that epigenetic 
modifications may influence HBV replication and persistent infection. Epigenetic therapy, a 
novel strategy targeting epigenetic modifications, was first applied successfully to leukemia 
treatment(11). To date, evidence is accumulating that the epigenetic mechanisms are responsible 
for HBV persistence and clearance, which indicates that epigenetic therapy possesses potentials 
to be a novel approach to treat CHB and may even cure it. In this review, we attempt to provide 
an overview of the epigenetic regulations of HBV infection and the possible therapeutic 
strategies for CHB from the lessons of cancer and other viral diseases.  
 
HBV LIFE CYCLE AND CCCDNA BIOLOGY 
HBV is the prototype of the Hepadnaviridae family, a small enveloped DNA virus with a 
partially double-stranded relaxed circular (rc) genome of 3.2kb. The infection begins when HBV 
virion binds with low affinity to heparansulfate proteoglycans (HSPG), followed by specific 
binding of preS1 domain of the large surface antigen (LHBsAg) with the viral receptor on the 
surface of the hepatocyte, which is the sodium taurocholate cotransporting polypeptide 
(NTCP)(12). However, how the virus is endocytosed into the cytoplasm has not been completely 
demonstrated(13). After uncoating, rcDNA in the HBV nucleocapsid is translocated into the 
nucleus and converted into cccDNA minichromosome. The detailed molecular mechanisms of 
nucleocapsid disassembly and cccDNA biosynthesis remain elusive. Using cccDNA as 
transcription template, HBV transcripts are generated by host RNA polymerase II machinery, 
including the 3.5kb pregenomic RNA (pgRNA) which encodes viral polymerase (pol) and HBV 
core protein (HBc), the 3.5kb preCore mRNA for translation of e-antigen (HBeAg), the 
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2.4/2.1kb preS/S mRNA encoding the large (L), middle (M) and small (S) HBsAg, and a 0.7kb 
mRNA encoding the regulatory protein HBx(14). In the cytoplasm, HBc proteins package pol 
and pgRNA and assemble into nucleocapsid, in which the pgRNA is reverse transcribed into 
rcDNA by the pol. After rcDNA is made, the capsid can be either coated by viral envelope for 
virion egress or redirected to the nucleus to replenish the cccDNA pool (Fig.1).  
 
In the nucleus, similar to other nuclear viral episomal DNA, HBV cccDNA exhibits as individual 
minichromosomes with cellular chromatin-like structures(9,10). Nucleosomes are nonrandomly 
positioned on the cccDNA of duck hepatitis B virus (DHBV), suggesting that, like host cellular 
chromatin, nucleopositioning and histone modifications of the cccDNA may regulate its 
transcription(15). cccDNA minichromosome is stably maintained in quiescent hepatocytes with a 
long half-life and is responsible for the persistence of infection during the natural course of 
chronic infection and prolonged antiviral treatment(7,16). HBV is not a cytopathic virus per se 
and most of hepatocytes in the adult liver are quiescent, however, the proliferation rate of 
hepatocytes can be greatly enhanced by liver inflammation and regeneration caused by viral 
infection (17,18). cccDNA appears not to be tethered to the host chromosome during mitosis, 
thus cccDNA are randomly partitioned into daughter cells and some of them are lost during cell 
division(19). However, a complete loss of cccDNA solely by hepatocyte proliferation cannot be 
achieved in an immunodeficient mouse model without blocking virus spread(19,20). It is now 
accepted that, during the recovery phase of an acute HBV infection, both CD8
+
 cytotoxic T cell 
(CTL)-mediated cytolytic and noncytolytic antiviral responses are responsible for the clearance 
of infection(14,21). Interestingly, cccDNA still can be detected in a significant percentage of 
fully recovered (“cleared”) patients(7,22), and reactivation of HBV infection in these patients 
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under immunosuppression conditions or chemotherapy is not uncommon(23), suggesting that 
cccDNA is inherently stable and it might be difficult to get rid of the very last copy, but silencing 
the activity of cccDNA, such as epigenetic modifications, might be a more realistic and practical 
way to control hepatitis B. 
 
EPIGENETIC CONTROL OF HBV INFECTION 
 
HBV DNA Methylation  
DNA methylation usually occurs at the 5’ position of cytosine ring within CpG dinucleotides by 
DNA methyltransferases (DNMTs) in mammalian cells and is generally associated with 
transcription silencing(24).  
 
The HBV cccDNA genome contains three predicted CpG islands: (1) the region overlapping the 
start site of the S gene (Island 1); (2) the region encompassing enhancer I, the HBx gene 
promoter (Xp), and the core promoter (Cp) (Island 2); (3) the region harboring the Sp1 promoter 
and the start codon of the pol gene (Island 3) (Fig.2)(25,26). Among the 10 distinct genotypes 
(A-J) of  HBV, the methylation rates in Island 1 are variable, while Island 2 and 3 are more 
conserved across genotypes(26). Methylation of the CpG islands on HBV cccDNA regulates 
HBV replication and gene expression. Zhang et al., demonstrated that cccDNA CpG Island 1 is 
seldom methylated, methylation of CpG Island 2 is associated with low viremia, and methylation 
of CpG Island 3 may contribute to a lower serum HBsAg level in CHB patients(27). Moreover, 
the methylation of CpG Island 3 is significantly correlated with hepatocarcinogenesis(28). In 
Page 7 of 29
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
 8
vitro study has shown that CpG Island 2 methylations negatively affected pgRNA transcription 
and reduced viral DNA replication(27).  
 
The role of DNMTs in HBV DNA methylation has not been clearly identified. In vitro studies 
reported that DNMT1, DNMT2, and DNMT3 expression is upregulated in response to HBV, 
leading to viral and host DNA hypermethylation and decreased HBV replication(29), but the 
underlying mechanism for HBV-mediated upregulation of DNMTs is unclear. It is worth noting 
that DNA methylation only occurs on the nuclear HBV DNA forms, but not the histone-free 
cytoplasmic core DNA or virion DNA(25,27,28). In the nucleus, the integration of HBV DNA 
into the human chromosome was frequently detected in HCCs from CHB patients, although it’s 
not essential of the viral life cycle(30). The integrated HBV DNA is replication-defective, but it 
can express HBsAg and/or an HBx fusion protein, which may contribute to virus persistence and 
hepatocarcinogenesis(30). A previous study has demonstrated that the integrated HBV DNA are 
methylated and silenced in the SNU398 HCC cell line(28). However, whether the episomal 
cccDNA and the integrated DNA are methylated by same or different mechanism remains 
unknown. Viral DNA methylation has been identified as a host defense mechanism since it often 
leads to the downregulation of viral gene expression(31), thus methylating the nuclear HBV 
DNA may represent a novel antiviral strategy for HBV treatment.  
 
Histone modifications of the cccDNA Minichromosome 
Nucleosome-associated histones can undergo a great deal of post-translational modifications 
(PTMs), which include acetylation, methylation, phosphorylation, ubiquitination, and many 
others within their N-terminal tails(32). The enzymes that add and remove such modifications 
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are histone acetyltransferases (HATs) and deacetylases (HDACs), lysine (K) methyltransferases 
(KMTs) and demethylases (KDMs), kinases and phosphatases, ubiquitin ligases and 
deubiquitinases, and so on(32,33). Genome-wide studies revealed that various combinations of 
modifications in a specific genomic region can lead to either activation or repression of gene 
expression (32). Histone acetylation and methylation have been well characterized. For instance, 
trimethylation of lysine 4, 36 or 79 on H3 (H3K4me3, H3K36me3, and H3K79me3, 
respectively), and acetylation of H3K9, H3K27 and H3K122 (H3K9ac, H3K27ac and H3K122ac) 
contribute to gene activation, whereas di- or trimethylation of H3K9 (H3K9me2 and H3K9me3) 
and trimethylation of H3K27 (H3K27me3) lead to transcriptional repression(32–34). Similarly, 
arginine methylation also plays a role in gene expression. Asymmetrical dimethylation on H4R3 
(H4R3me2a) is associated with transcription activation, while symmetrical methylation on H4R3 
(H4R3me2s) is linked to transcriptional repression(35).  
 
The PTMs of histones and non-histone proteins that either directly bind to cccDNA sequence or 
bind to cccDNA minichromosome through protein-protein interactions have become a hot area 
of research. A growing body of evidence suggests that histone modifications on cccDNA 
regulate the viral transcription. The HBc and HBx proteins, H3 and H4 histones, cellular 
transcription factors (CREB, ATF, YY1, STAT1 and STAT2), and chromatin modification 
enzymes (PCAF/GCN5, p300/CBP, HDAC1, SIRT1, PRMT1, PRMT5 and EZH2) have been 
shown to be associated with cccDNA by using chromatin immunoprecipitation (ChIP) assays 
(10,36–40) (Fig.3). Hypoacetylation of the cccDNA-associated H3 and H4 histones and the 
recruitment of the cellular HDAC1 onto cccDNA are associated with low HBV replication in 
vitro and in vivo(37). The presence of class I/II histone deacetylase inhibitors (HDACis), 
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valproic acid and trichostatin A (TSA), have been shown to induce an evident increase of  
cccDNA-bound acetylated H3 and H4 histones and HBV replication in the linear monomeric  
HBV DNA transfected Huh7 cells(37), suggesting a direct effect of the PTMs on HBV  
transcription. However, another study using DHBV stable cell line system showed that certain  
HDACis, including TSA, suppressed cccDNA transcription and reduced DHBV replication,  
indicating that a cellular function sensitive to HDACi might be required for DHBV cccDNA  
transcription(41). Such discrepancy between these two studies might be due to virus-specific  
(HBV vs. DHBV) and/or cell-specific (human vs. avian) reasons. Recently, the first genome- 
wide map of PTMs on cccDNA chromatin revealed high levels of PTMs associated with active  
transcription (H3K4me3, H3K27ac, and H3K122ac) enriched at specific sites within the HBV  
genome from infected cell cultures and liver tissue, but very low levels of PTMs linked to  
transcriptional repression even at silent HBV promoters (42), suggesting that the transcription  
activity of cccDNA is predominantly determined by those transcriptionally active PTMs.  
  
H3K4me3 modification by MLL3, a component of ASCOM complex, has been shown to be   
critical for activating NTCP gene transcription by nuclear receptors in HepG2 cells(43).  
Considering that NTCP is a functional receptor for HBV, H3K4me3 modification of NTCP  
promoter by MLL3 may facilitate HBV infection in vivo. In line with this, Tropberger and  
colleagues found that cccDNA possesses a high level of H3K4me3 (42), which suggests that  
MLL3 might be involved in shaping the histone PTMs of cccDNA. H3K27ac blocks polycomb- 
mediated H3K27me3, and H3K27ac is also widely used to identify active enhancers(44). EZH2  
is a subunit of PRC2 and has the KMT activity on H3K27. Interestingly, a recent knockdown  
study of EZH2 showed the upregulation of HBeAg and HBsAg, indicating a repressive function  
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of EZH2 on HBV gene expression(40). H3K122ac is enriched at genetic elements associated  
with transcriptionally active genomes in vivo and is catalyzed by the transcriptional coactivator  
p300/CBP(45). Despite the coexistence of H3K122ac with other H3 tail acetylation in the same  
nucleosome, H3K122ac alone can be sufficient to stimulate transcription(46). According to the  
RNAi-based screening of known histone methyltransferases (SUV39H, G9a, EZH2, and PRMT5)  
and demethylases (LSD1, KDM5A, and KDM2A), Zhang et al., revealed that the PRMT5- 
mediated H4R3me2s repressed cccDNA transcription. In addition, PRMT5-mediated H4R3me2s  
interacted with HBc and the Brg1-based hSWI/SNF chromatin remodeler, which accounted for  
the reduced binding of RNA polymerase II to cccDNA(40).   
  
The viral regulatory protein HBx serves as a promiscuous transactivator of the viral and cellular  
promoters. HBx activates the transcription of host genes by interacting directly with nuclear  
transcription factors or by activating various signal transduction pathways in the cytoplasm and  
has been proven to be a potent epigenetic modifying factor in liver(47). HBx has been shown to  
activate HBV transcription through its recruitment onto cccDNA by host PCAF/GCN5, p300,  
and CBP acetyltransferases; and inhibit cellular factors involved in chromatin regulation, such as  
PP1/HDAC1 complex(38,48) (Fig.3A). Conversely, in the absence of HBx, the rapid  
hyperacetylation of cccDNA-bound histones by p300 is severely impaired, but the deacetylases  
HDAC1 and SIRT1 are recruited to cccDNA, leading to the suppression of cccDNA  
transcription and viral replication(38) (Fig. 3B). In addition, without HBx, the silenced HBV  
genome is not only associated with histone deacetylation but also with the deposition of  
repressive markers (H3K9me2 and H3K9me3) by SETDB1(48). Recently, HBx was shown to  
interact with DNA damage-binding protein 1 (DDB1) and recruit the cullin 4A-RING E3  
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ubiquitin ligase (CRL4), the assembled CRL4-DDB1 complex ubiquitinates the Smc5/6 complex  
for proteasomal degradation to activate cccDNA transcription(49,50), indicating that Smc5/6  
complex may epigenetically silence cccDNA through histone PTMs in the absence of HBx(51)  
(Fig.3).   
  
Although a series of histone modifications of HBV cccDNA minichromosome have been  
reported, the cccDNA-specific PTM enzymes have not been identified yet. We summarize herein  
the KMTs, KDMs, HATs, HDACs, and other factors determined in cancer research (Table 1),  
which may provide candidates for the future study of PTMs of HBV cccDNA-associated  
histones.  
  
DEVELOPMENT OF EPIGENETIC THERAPY FOR CHRONIC HBV INFECTION   
The pool of cccDNA is highly stable and persists in the hepatocytes. Currently available and  
experimental antivirals are interferons, inhibitors of reverse transcription, allosteric modulators  
of capsid assembly, cccDNA formation inhibitors, inhibitors of virus entry or release of viral or  
subviral particles, but their impact on the reduction of pre-existing cccDNA is limited(4,5).  
Alternatively, further understanding of epigenetic mechanisms in the HBV infection may  
promote the development of “epigenetic therapy” to hopefully silence HBV in infected  
hepatocytes. Drugs against epigenetic targets (“epidrugs”) have been developed and some have  
been approved for selected cancers. Epigenetic discoveries continually define not only promising  
new targets for anti-cancer and antiviral therapy but also the ways to repurpose drugs already  
used in the clinic. The elucidation of these alteration pathways has attracted much attention to the  
dysregulation of epigenetics in disease and also the development of novel epidrugs. In principle,  
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epigenetic therapy generally targets one or more of three protein categories: Writers, enzymes  
that establish epigenetic marks (e.g. DNMTs and HATs); Readers, proteins which recognize  
epigenetic regulations (e.g. proteins of the bromo and extra terminal family, BET, which are  
readers of histone acetylation) and may bring in other protein complexes to change gene  
expression; and Erasers, enzymes that remove epigenetic marks (e.g. HDACs and KDMs)(8)  
(Table 1). A growing body of studies on the epigenetic therapies in chronic viral infections, such  
as HIV and EBV(52,53), suggest that epigenetic therapy might be a promising therapeutic  
strategy for CHB.   
  
Targeting DNA methylation of cccDNA  
DNA methylation of viral genomes has been identified as a host defense mechanism(31).  
Increased expression of DNMTs has been reported to facilitate the methylation of the viral  
genome to impede HBV replication in vitro(29), which suggests that DNMT could be utilized to  
inhibit cccDNA transcription. However, on the other hand, host DNA methylation has been  
shown to be a major mechanism for inactivating relevant tumor suppressor genes in HCC(54),  
indicating an impossibility to directly use strong demethylation agents in the treatment of HCC.  
5-azacytidine and 5-aza-2’-deoxycytidine are FDA-approved DNMT inhibitors (DNMTis).  
However, Azacitidine is contraindicated in patients with advanced hepatic tumors due to  
potential hepatotoxic effect(55). Therefore, for HBV-related HCC, the balance between blocking  
HBV infection and inhibition of host tumor-suppressor genes should be taken into careful  
consideration in the development of DNMT-based therapeutics. Several molecules interfering  
with the DNMTs activity are under the various phases of clinical trials for the treatment of  
several kinds of cancers(56), their effects on HBV cccDNA and HCC await further  
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investigations. Studies with several cancer cell lines demonstrated that (−)-epigallocatechin-3-
gallate (EGCG) can alter DNMTs activity(57). In addition, EGCG also has been shown to inhibit 
HBV entry and induce anti-HBV autophagy response(58,59), indicating that EGCG may be 
beneficial to HBV-related HCC patients.  
 
It has been reported that HBV infection induced de novo methylation and decreased expression 
of antiviral cytokine IL-4(60). Furthermore, DNMTis have been shown to upregulate cytokines 
as well as JAK/STAT and IFN signaling pathways in cancer patients(61). Hence, DNMT-based 
epigenetic therapy may also evoke the innate immunity in both HBV-infected cells and immune 
cells to systematically enhance the suppression of HBV replication. 
 
Targeting histone modifications of cccDNA 
Recognition of the role of histone PTMs in cccDNA transcription provides several potential 
therapeutic targets to inhibit the cccDNA. Although the genome-wide mapping of PTMs on 
cccDNA minichromosome showed that the levels of transcriptional active PTMs, but not the 
repressive PTMs, determine the activity of cccDNA(42); but these PTMs also play similar roles 
in host chromosome transcription. Thus, the cccDNA-specific PTM modifiers, if any, will hold 
great promise for the development of therapeutic targets. In this regard, a recent study 
demonstrated that a multifunctional protein arginine methyltransferase PRMT5 preferentially 
induced H4R3me2s on cccDNA to repress viral transcription, indicating that certain PTM 
enzymes may be able to distinguish the host chromosome from HBV cccDNA for chromatin 
modifications(40). Furthermore, Tropberger et al., found that HAT inhibitor C646 blocked 
histone acetyltransferases p300/CBP for H3K27ac and H3K122ac and inhibited HBV 
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transcription without measurable cytotoxicity in PHHs(42), which provides a proof of concept  
that epigenetic compounds may represent a novel class of HBV antivirals.  
  
Here, we discuss the current anti-HBV therapies that may affect cccDNA histone modification,  
as well as other successful cases of epigenetic therapy for other diseases. Since 2006, a number  
of HDACis have been approved by the FDA as anti-cancer drugs (vorinostat, romidepsin,  
belinostat, panobinostat, etc.). Nowadays, the study of HCC treatment using epidrugs is a  
cutting-edge area of research. Inhibition of deacetylation by HDACis has been shown to enhance  
HBV transcription and replication in vitro(37,62). In addition, HDACis may also potentially  
reactivate latent DNA virus infection in patients receiving it as anticancer drugs(63). IFN-α is the  
only approved immunomodulator for CHB treatment(4). Recent studies suggested that its  
antiviral function involves epigenetic modification of cccDNA minichromosome. When treating  
the HBV-infected cells and chimeric uPA/SCID mice with IFN-α, the transcription activity of  
cccDNA was inhibited through the hypoacetylation of cccDNA-associated histones and the  
recruitment of transcriptional repressor complex YY1 and EZH2, and HDAC1 and SIRT1 onto  
cccDNA(36). The reduction of H3K27ac and H3K122ac, which are markers of active  
transcription, was observed on cccDNA under IFN-α treatment, suggested that IFN-α could  
activate PTM-modifying enzymes and lead to a transcriptionally less permissive cccDNA  
chromatin state(42). Another study also indicated that avian IFN-α treatment interferes with the  
structure and function of DHBV cccDNA minichromosome by reducing the acetylation of both  
H3 and H4 histones(41).   
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It is known that IFN-α engages the IFN-α/ß receptor complex to modulate the transcription of the  
IFN stimulated genes (ISGs) via JAK/STAT signaling pathway to evoke innate antiviral  
responses against viral infection(64). However, IFN-α monotherapy shows low response rate  
with severe adverse effects in CHB patients(65). Considering that both the host ISG expression  
and viral cccDNA transcription are regulated by epigenetic modifications, combining IFN-α with  
epidrugs might be able to rapidly achieve a more potent inhibition of cccDNA and reduce side  
effects. “Shock and Kill” is one of the most discussed and tested therapeutic strategies against  
HIV-1, which refers to the induction of latent provirus by various latency-reversing agents,  
followed by  elimination of the infected cells by immune system or by cell lysis induced by viral  
cytopathic effect and prevention of new infection by combined antiretroviral therapy(52). DNMT,  
KMT, and HDAC inhibitors have been employed in activating latent reservoir of HIV-1(66). In  
terms of HBV, high-dose IFN-α treatment has been reported to lead to cccDNA degradation  
through APOBEC3A-mediated cytidine deamination of one strand of cccDNA, by which induces  
mismatch mutations in cccDNA for Apurinic/Apyrimidinic-endonuclease-1-mediated  
degradation(67). Under IFN-elicited antiviral responses, it is assumed that HDACis treatment  
will loosen the structure of cccDNA minichromosome for transcription and thus increase the  
possibilities for APOBEC3A to edit cccDNA for degradation. With such potential synergy  
between IFN-α and epigenetic treatment, possible drawbacks should be avoided to move the  
approach forward. Firstly, IFN-induced APOBEC3s may facilitate the mutation of HBV DNA to  
assist the viral evolution, potentially resulting in immune escape and acceleration of HCC  
development(68). Secondly, HDACis are notorious for their toxic effects on platelet counts in  
vivo, in addition to the risk of reactivation of latent virus, such as HSV-1 and EBV(63), perhaps  
enhancing HBV as well if the enhancement overrides IFN’s antiviral effect under combination. If  
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these problems can be solved, it may be then possible to repurpose HDACis as potential  
therapeutic agents against cccDNA in CHB patients.   
  
POTENTIAL FOR DEVELOPMENT OF EPIGENETIC THERAPY COMBINED WITH  
IMMUNOTHERAPY   
Previous studies revealed that epigenetic cancer therapy can modulate the expressions of tumor  
suppressor genes, tumor-associated antigens (TAAs), and genes involved in immune response.  
The genes encoding TAAs are essential for T cell activation and tumor recognition by the  
immune system(69). Epigenetic regulation of host immune cells development and differentiation  
has also been well described(70). DNMTis can induce the expression of MHC-I molecules,  
which present epitopes to T cells and direct CTLs to lyse tumor cells(71). HDACis can affect the  
polarization of naïve CD4
+
 T cells toward Th1 and Th2 subsets(72). Hypomethylating agents  
increase the production of cytokines, including IL-2, TNF-α, and IFN-γ, to kill tumor cells(73).  
For HBV, T cell-derived cytokines, TNF-α and IFN-γ, which induce APOBEC3A and  
APOBEC3B, may contribute to the cccDNA loss in a non-cytolytic fashion(74). Meanwhile,  
epidrugs also facilitate the killing of tumor cells through stimulating NK cells and CTLs(69). It is  
well acknowledged that CTL exhaustion/tolerance contributes to CHB, thus the epigenetic  
therapy may possess a chance to restore T cell functions against HBV, and future epigenetic  
therapy combined with immunotherapy (including the aforementioned IFN-α therapy) may hold  
promise for curing CHB.   
  
CONCLUSION AND PERSPECTIVE  
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Since the term “epigenetics” was coined more than 70 years ago, study on epigenetic  
modifications in normal and disease biology has grown to a major field of research (8,34,63).  
Accumulating evidence supports that epigenetic regulation of cccDNA plays important roles in  
HBV reproduction. The desired end-point of HBV therapy is the elimination of cccDNA, or at  
least a complete inactivation of cccDNA, in the host, which cannot be achieved by the current  
antivirals. All these urge a need for developing epigenetic HBV therapies to target cccDNA. To  
this end, screening of available epidrugs or larger compound libraries in cccDNA reporter cell  
lines or HBV infection cell culture systems would be the first attempt. In addition, the cccDNA- 
bound HBc and HBx are also attractive antiviral targets. HBc and HBx destabilizers or allosteric  
modulators may potentially alter the epigenetics of cccDNA and lead to transcriptional silencing  
or other antiviral effects. On the other hand, the genetic and epigenetic alterations of host  
chromosome caused by HBV infection are believed to play important roles in viral persistence  
and the development of HCC in CHB patients. Hence, epigenetic therapy may be a “two birds,  
one stone” approach to treat both CHB and HBV-related HCC. In cancer therapies, epidrugs has  
demonstrated their therapeutic values, together with many other beneficial effects on the host,  
such as innate and adaptive immune activations and reduced chemotherapy resistance(61,69). In  
addition, some epidrugs have synergy with other epigenetic therapies, chemotherapies or  
immunotherapies(61). According to the available information about cccDNA biology and  
epigenetic therapy as we discussed in this review, it is envisioned that, in the near future,  
cccDNA-specific epigenetic mechanisms can be fully elucidated, and cccDNA-specific epidrugs  
can be developed to treat and even cure CHB.   
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Figure Legend  
Fig 1. HBV life cycle. The major steps in HBV life cycle including entry, trafficking, cccDNA  
formation, mRNA transcription, pgRNA encapsidation, DNA replication, viral particle assembly  
and secretion are shown. (Abbreviations: HSPG, heparan sulfate proteoglycan; MVB,  
multivesicular body; NTCP, sodium taurocholate cotransporting polypeptide.)  
Fig 2. Schematic representation of the open reading frames (ORFs) of preC/Core, pol, preS/S,  
and X in HBV genome (genotype A, GenBank: AB116086); the four promoters, Cp, Sp1, Sp2,  
and Xp; the regulatory elements, enhancer 1 and 2 (EN1 and EN2); and three predicted CpG  
islands.   
Fig 3. Schematic representation of modification status of HBV cccDNA-assoicated histones  
and the recruitment of chromatin modifying enzymes on cccDNA in relation to HBx. (A) In  
the presence of HBx, cccDNA-bound histones are hyperacetylated, viral minichromosome is in  
an open configuration and viral gene transcription is activated, leading to a high level of virus  
replication. (B) In the absence of HBx, host restriction factors, such as Smc5/6 complex and  
PRMT1, are loaded on cccDNA. The cccDNA-bound histones are hypoacetylated, viral  
minichromosome is in a closed configuration and viral gene is transcriptionally repressed,  
resulting in a low level of virus replication. (Abbreviations: H3/H4 Ac, aceylated histone 3 and 4;  
CBP, CREB-binding protein; PCAF, p300/CBP-associated factor; PRMT1, protein arginine  
methyltransferase 1 PRMT5, protein arginine methyltransferase 5; SIRT1, sirtuin 1; HDAC1,  
histone deaceyltransferase 1; EZH2, enhancer of zeste homolog 2; SUV39H, suppressor of  
variegation 3-9 Homolog; HP1: heterochromatin protein 1 factors; SETDB1: SET Domain  
Bifurcated 1. Smc5/6: Structural maintenance of chromosomes protein 5/6.)   
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Table 1. List of major epigenetic modifiers in human cells. 
 
 
 
Category Gene Reference 
Writers:   
DNMTs DNMT1, DNMT2, DNMT3A, DNMT3B (8,29,34) 
HATs CBP, p300, KAT5, KAT6A, KAT6B, KAT7 (8,32–34,38) 
KMTs MLL, EZH2, NSD1, NSD2, DOT1L, SETD1, SETD7, 
SMYD2, SMYD3, G9a/GLP, PRDM2, SUV39H1 
(8,32–35,40,43,47) 
 
Readers: 
  
Histone-modified 
binding proteins 
BRD2, BRD3, BRD4, SMARCA2, SMARCA4, 
SMARCB1, BAZ2A, PB1, BRPF1, ATAD2, L3MBTL3, 
WDR5, BRD7, BRD9, CBX7, ING1, ING2, ING3, 
ING4, ING5, MTA1, MTA2, MTA3, CHD5, CHD7, 
ARID1A  
(8,34) 
Methyl-CpG binding 
proteins 
MBD1, MBD2, MBD4, MECP2 (34) 
 
Erasers: 
  
HDACs HDAC1, HDAC2, HDAC6, SIRT1, SIRT2, SIRT3, 
SIRT7 
(8,32,34,38) 
KDMs KDM1A(LSD1), KDM2B, KDM4C, KDM5A, KDM5B, 
KDM6A, KDM6B 
(8,32–34,40) 
(2OG)-Fe(II)-dependent 
oxygenases 
TET1, TET2 (34) 
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Fig 1. HBV life cycle. The major steps in HBV life cycle including entry, trafficking, cccDNA formation, mRNA 
transcription, pgRNA encapsidation, DNA replication, viral particle assembly and secretion are shown. 
(Abbreviations: HSPG, heparan sulfate proteoglycan; MVB, multivesicular body; NTCP, sodium taurocholate 
cotransporting polypeptide.)  
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Fig 2. Schematic representation of the open reading frames (ORFs) of preC/Core, pol, preS/S, and X in HBV 
genome (genotype A, GenBank: AB116086); the four promoters, Cp, Sp1, Sp2, and Xp; the regulatory 
elements, enhancer 1 and 2 (EN1 and EN2); and three predicted CpG islands.  
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Fig 3. Schematic representation of modification status of HBV cccDNA-assoicated histones and the 
recruitment of chromatin modifying enzymes on cccDNA in relation to HBx. (A) In the presence of HBx, 
cccDNA-bound histones are hyperacetylated, viral minichromosome is in an open configuration and viral 
gene transcription is activated, leading to a high level of virus replication. (B) In the absence of HBx, host 
restriction factors, such as Smc5/6 complex and PRMT1, are loaded on cccDNA. The cccDNA-bound histones 
are hypoacetylated, viral minichromosome is in a closed configuration and viral gene is transcriptionally 
repressed, resulting in a low level of virus replication. (Abbreviations: H3/H4 Ac, aceylated histone 3 and 4; 
CBP, CREB-binding protein; PCAF, p300/CBP-associated factor; PRMT1, protein arginine methyltransferase 1 
PRMT5, protein arginine methyltransferase 5; SIRT1, sirtuin 1; HDAC1, histone deaceyltransferase 1; EZH2, 
enhancer of zeste homolog 2; SUV39H, suppressor of variegation 3-9 Homolog; HP1: heterochromatin 
protein 1 factors; SETDB1: SET Domain Bifurcated 1. Smc5/6: Structural maintenance of chromosomes 
protein 5/6.)  
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